Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation

被引:1
|
作者
Koster, Eva A. S. [1 ]
von dem Borne, Peter A. [1 ]
van Balen, Peter [1 ]
Marijt, Erik W. A. [1 ]
Tjon, Jennifer M. L. [1 ]
Snijders, Tjeerd J. F. [2 ]
van Lammeren, Danielle [3 ]
Veelken, Hendrik [1 ]
Falkenburg, J. H. Frederik [1 ]
Halkes, Constantijn J. M. [1 ]
de Wreede, Liesbeth C. [4 ]
机构
[1] Leiden Univ, Med Ctr, Med Ctr, Leiden, Netherlands
[2] Dept Hematol, Med Spectrum Twente, Enschede, Netherlands
[3] Dept Hematol, HagaZiekenhuis, The Hague, Netherlands
[4] Leiden Univ, Dept Biomed Data Sci, Med Ctr, Leiden, Netherlands
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
allogeneic stem cell transplantation; donor lymphocyte infusion; graft-versus-host-disease; acute myeloid leukemia; acute lymphoblastic leukemia; myelodysplastic syndrome; multi-state modelling; FREE SURVIVAL; IMMUNE RECONSTITUTION; TREATMENT SUCCESS; MYELOID-LEUKEMIA; LANGERHANS CELLS; PLASMA-LEVELS; IMPACT; CHIMERISM; RELAPSE; ALLOREACTIVITY;
D O I
10.3389/fimmu.2024.1335341
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Unmodified donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (alloSCT) can boost the beneficial Graft-versus-Leukemia (GvL) effect but may also induce severe Graft-versus-Host-Disease (GvHD). To improve the balance between GvL and GvHD, it is crucial to identify factors that influence the alloreactivity of DLI. Methods We investigated the effects of the presence of patient-derived antigen-presenting cells at time of DLI as estimated by the bone marrow (BM) chimerism status, lymphopenia as measured by the absolute lymphocyte count (ALC) at time of DLI, and the presence of a viral infection (de novo or reactivation) close to DLI on the risk of GvHD after DLI. The cohort consisted of patients with acute leukemia or myelodysplastic syndrome who prophylactically or pre-emptively received DLI as standard care after alemtuzumab-based alloSCT. In patients at high risk for relapse, DLI was administered at 3 months after alloSCT (n=88) with a dose of 0.3x10(6) or 0.15x10(6) T cells/kg in case of a related or unrelated donor, respectively. All other patients (n=76) received 3x10(6) or 1.5x10(6) T cells/kg, respectively, at 6 months after alloSCT. Results For both DLIs, patients with reduced-intensity conditioning and an unrelated donor had the highest risk of GvHD. For DLI given at three months, viral infection within 1 week before and 2 weeks after DLI was an additional significant risk factor (hazard ratio (HR) 3.66 compared to no viral infection) for GvHD. At six months after alloSCT, viral infections were rare and not associated with GvHD. In contrast, mixed BM chimerism (HR 3.63 for >= 5% mixed chimerism compared to full donor) was an important risk factor for GvHD after DLI given at six months after alloSCT. ALC of <1000x10(6)/l showed a trend for association with GvHD after this DLI (HR 2.05 compared to >= 1000x10(6)/l, 95% confidence interval 0.94-4.45). Furthermore, the data suggested that the presence of a viral infection close to the DLI at three months or >= 5% mixed chimerism at time of the DLI at six months correlated with the severity of GvHD, thereby increasing their negative impact on the current GvHD-relapse-free survival. Conclusion These data demonstrate that the risk factors for GvHD after DLI depend on the setting of the DLI.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] RISK FACTORS FOR THE DEVELOPMENT OF GRAFT-VERSUS-HOST-DISEASE FOLLOWING DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
    Koster, Eva
    von dem Borne, Peter
    van Balen, Peter
    Marijt, Erik
    Tjon, Jennifer
    Snijders, Tjeerd
    van Lammeren, Danielle
    Veelken, Hendrik
    Falkenburg, Frederik
    de Wreede, Liesbeth
    Halkes, Constantijn
    BONE MARROW TRANSPLANTATION, 2024, 59 : 240 - 241
  • [2] αβ-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation
    Kordelas, L.
    Buttkereit, U.
    Lindemann, M.
    Koldehoff, M.
    Klisanin, V.
    Horn, P. A.
    Fleischhauer, K.
    Beelen, D. W.
    BONE MARROW TRANSPLANTATION, 2017, 52 (12) : 1668 - 1670
  • [3] αβ-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation
    L Kordelas
    U Buttkereit
    M Lindemann
    M Koldehoff
    V Klisanin
    P A Horn
    K Fleischhauer
    D W Beelen
    Bone Marrow Transplantation, 2017, 52 : 1668 - 1670
  • [4] Reconstitution of regulatory T-cell subpopulations after allogeneic haematopoietic stem cell transplantation and graft-versus-host-disease
    Xhaard, A.
    Moins, H.
    Busson, M.
    Robin, M.
    Ribaud, P.
    Dhedin, N.
    Abbes, S.
    Carmagnat, M.
    Toubert, A.
    Socie, G.
    de Latour, R. Peffault
    BONE MARROW TRANSPLANTATION, 2013, 48 : S11 - S12
  • [5] Influence of graft source on graft versus host disease, relapse and survival following T-cell depleted allogeneic stem cell transplantation
    Barge, RMY
    Brouwer, RE
    Starrenburg, CWJ
    Zwinderman, AH
    Hale, G
    Waldmann, H
    den Ottolander, GJ
    Falkenburg, JHF
    Willemze, R
    Fibbe, WE
    BONE MARROW TRANSPLANTATION, 2001, 27 : S178 - S178
  • [6] Reconstitution of Regulatory T Cell Subpopulations After Allogeneic Hematopoietic Stem Cell Transplantation and Graft-Versus-Host-Disease
    Xhaard, Alienor
    Moins, Helene
    Busson, Marc
    Carmagnat, Maryvonnick
    Robin, Marie
    Ribaud, Patricia
    Dhedin, Nathalie
    Abbes, Sarah
    Toubert, Antoine
    Socie, Gerard
    de Latour, Regis Peffault
    BLOOD, 2012, 120 (21)
  • [7] Feasibility of very low dose donor lymphocyte infusion early after T-cell depleted allogeneic stem cell transplantation
    von dem Borne, P. A.
    Halkes, C. J. M.
    Marijt, E. W.
    Veelken, H.
    Falkenburg, J. H. F.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S318 - S318
  • [8] Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation
    Ko K. Maung
    Benny J. Chen
    Ian Barak
    Zhiguo Li
    David A. Rizzieri
    Cristina Gasparetto
    Keith M. Sullivan
    Gwynn D. Long
    Ashley M. Engemann
    Barbara Waters-Pick
    Krista Rowe Nichols
    Richard Lopez
    Yubin Kang
    Stefanie Sarantopoulos
    Anthony D. Sung
    Nelson J. Chao
    Mitchell E. Horwitz
    Bone Marrow Transplantation, 2021, 56 : 137 - 143
  • [9] Phase I, Dose Escalation Study of Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation
    Maung, Ko Ko
    Chen, Benny J.
    Rizzieri, David A.
    Gasparetto, Cristina
    Sullivan, Keith
    Long, Gwynn D.
    Engemann, Ashley Morris
    Waters-Pick, Barbara
    Nichols, Krista Rowe
    Lopez, Richard
    Kang, Yubin
    Sarantopoulos, Stefanie
    Sung, Anthony D.
    Chao, Nelson J.
    Horwitz, Mitchell E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [10] Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation
    Maung, Ko K.
    Chen, Benny J.
    Barak, Ian
    Li, Zhiguo
    Rizzieri, David A.
    Gasparetto, Cristina
    Sullivan, Keith M.
    Long, Gwynn D.
    Engemann, Ashley M.
    Waters-Pick, Barbara
    Nichols, Krista Rowe
    Lopez, Richard
    Kang, Yubin
    Sarantopoulos, Stefanie
    Sung, Anthony D.
    Chao, Nelson J.
    Horwitz, Mitchell E.
    BONE MARROW TRANSPLANTATION, 2021, 56 (01) : 137 - 143